EQS-News: GeoVax, Inc.: GeoVax Highlights Likely Sustained Clade Ib Mpox Transmission in the United States

GeoVax Labs, Inc. (GOVX) announced the development of a vaccine construct targeting Bundibugyo virus (BDBV) using its proprietary MVA-based rapid-cloning technology. The construct is a milestone toward a potential BDBV vaccine candidate, building on the company's existing filovirus vaccine portfolio. GeoVax's GEO-MVA vaccine for mpox and smallpox remains its primary focus, with a Phase 3 trial planned for late 2026. The World Health Organization (WHO) has called for accelerated development of BD

GeoVax Labs (NASDAQ:GOVX) says it plans to start a pivotal Phase 3 trial of its GEO-MVA mpox and smallpox vaccine before end-2024. The EMA granted an expedited pathway, waiving Phase 1 and 2, requiring an immunobridging study versus Bavarian Nordic’s MVA-BN. GeoVax cites a ~15 million dose annual MVA supply gap and targets government stockpiles.

GeoVax Labs (Nasdaq: GOVX) said it completed manufacturing, regulatory, clinical and preclinical milestones for its GEO-MVA pivotal Phase 3 immune-bridging study, scheduled to start in Q4 2026. The company expects a 500-participant trial and to report results in mid-2027, comparing GEO-MVA immune responses with licensed MVA-BN (Imvanex).

GeoVax Labs, Inc. (GOVX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex_993355.htm EXHIBIT 99.1 ex_993355.htm Exhibit 99.1 GeoVax Reports Second Quarter 2026 Financial Results and Provides Business Update Company Advances GEO-MVA Toward Planned Pivotal Immunobridging Study Under Expedited Regulatory Pathway ATLANTA, GA, July 27, 2026 – G

Argenx reported positive Phase 2 results for FB102 in celiac disease, meeting its primary endpoint. The company will advance FB102 into Phase 3. Separately, argenx discontinued the Phase 3 UNITY study of efgartigimod in Sjögren's disease due to futility. Shares fell 7.91% overnight.

Google, Meta, and other companies are investing nearly US$2 billion to create an open database for AI systems focused on biology, disease research, and drug discovery.